Fatty liver disease's renaming impacts on drug clinical trials
10.3760/cma.j.cn501113-20230801-00026
- VernacularTitle:脂肪性肝病再次更名对药物临床试验的影响
- Author:
Rui HUANG
1
;
Huiying RAO
Author Information
1. 北京大学人民医院 北京大学肝病研究所 丙型肝炎和肝病免疫治疗北京市重点实验室 非酒精性脂肪性肝病诊断北京市国际科技合作基地，北京 100044
- Keywords:
Fatty liver disease;
Metabolic associated fatty liver disease/Metabolic dysfunction-associated steatotic liver disease;
Nomenclature;
Drug clinical trial
- From:
Chinese Journal of Hepatology
2023;31(8):793-797
- CountryChina
- Language:Chinese
-
Abstract:
Fatty liver disease has undergone a major name change, with metabolic dysfunction-associated fatty liver disease (MASLD) replacing nonalcoholic fatty liver disease. The definition of MASLD no longer requires the exclusion of other co-existing liver diseases but instead associates hepatic steatosis with overweight/obesity, type 2 diabetes mellitus, or metabolic disorders and clearly defines the amount of alcohol consumption. The new definition also introduces the concepts of metabolic-related alcoholic liver disease and cryptogenic fatty liver disease. These changes will bring new challenges and opportunities for the design of clinical trials of fatty liver disease drugs and the selection of target populations.
